Cargando…
Empagliflozin in heart failure with preserved ejection fraction: first success in mission impossible
Heart failure and preserved ejection fraction (EF) is a common disease with a poor prognosis and increasing prevalence in the community. The current treatment paradigm includes symptomatic therapy, such as diuretics, risk factor control, and treatment of comorbidities. According to the most recent E...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9653132/ https://www.ncbi.nlm.nih.gov/pubmed/36380802 http://dx.doi.org/10.1093/eurheartjsupp/suac106 |